Eli Lilly to invest EUR 15m expanding its R&D center in Alcobendas in the next two years
Eli Lilly invertirá EUR 15m en la expansión de su centro I+D en Alcobendas en los próximos dos años
Intel ID : 366129
Relevant Documents
| Press Release | 12 Jun 2023 | Eli_Lilly_Nota_de_Prensa_2023.pdf | ES |
|
| Intel ID | 366129 | |
| Value | EUR 15,00m | |
| Native Currency | Euro (EUR) | |
|
Financial Data - Eli Lilly
(31 Dec 2013) |
Revenue: EUR 16,76m Exchange Rate: 
|
|
| Date |
 |
|
| Country | |
|
| Geography | |
|
| Subsector (Old TTR Sectors) |
|
|
| Primary Subsector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution (Primary) 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
|
| Type |
|
|
| Intel Grade |
|
|
| Source |
|
|
| Tags | |
Bidder
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.